Indication intelligence, analysis and sector perception

Organovo Holdings (ONVO) presents data on creating drug profile of chronic liver disease progression - BUY

April 12, 2018 8:24am

ONVO closed down -$0.01 to $1.01 and is UP +$0.04 or +$0.04 or +3.96

These new data points provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants.

ONVO presented data on modeling non-alcoholic fatty liver disease (“NAFLD”) using its 3D bio printed human liver tissues. This data was presented at The International Liver Congress™ by Dwayne Carter, Tissue Applications, at Organovo.

Organovo has developed its NAFLD disease model and can now demonstrate a progressive accumulation of fat over time, creating a window of disease progression onto which candidate drugs targeted at fat accumulation and disposition can be applied.

ONVO has also established that the NAFLD disease phenotype can be generated from multiple donor origin cells, and that the inherent variability between donors is reflected in the NAFLD model as variable susceptibility to tissue damage by NAFLD-promoting agents.

The Bottom Line: ONVO’s tissue systems have the potential to facilitate breakthrough translational research from target discovery to high-value drug profiling, enabling better understanding of disease processes, discovery of novel therapeutics, biomarkers, and the safety assessment of drugs in a disease-relevant background.

BUY

NAFLD is a chronic liver disease that often progresses into nonalcoholic steatohepatitis (“NASH”), and is characterized by lipid accumulation, inflammation, oxidative stress and fibrosis. NAFLD is now recognized as one of the most common causes of chronic liver disease, with an estimated prevalence of 25% worldwide, and is projected to become the leading cause of liver transplant by 2025. The study of NAFLD has historically used traditional cell and small animal models, which are time consuming to generate and do not mimic the complexity and multi-factorial nature of human liver disease. Furthermore, current 2D cell culture models lack relevant liver cell types, do not accurately display diseased phenotypes and have limited utility due to rapid loss of cell viability and function.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.